自我效能管理对恶性肿瘤放化疗患者癌痛症状及生活质量的影响

目的探讨自我效能管理对恶性肿瘤放化疗患者癌痛症状及生活质量的影响。方法选取2018年1月至2020年1月收治的78例恶性肿瘤放化疗患者作为研究对象,根据护理方法不同将其分为对照组和试验组,各39例。对照组行常规护理,试验组在常规护理基础上行自我效能管理。比较两组的疼痛程度及评分、生活质量评分、自我效能感评分及临床疗效。结果护理后,试验组轻度患者占比高于对照组,中重度患者占比及VAS评分低于对照组(P<0.05)。护理后,试验组躯体、认知、情绪、社会评分均高于对照组(P<0.05)。护理后,试验组疼痛管理、躯体功能、症状应对评分及总分均高于对照组(P<0.05)。试验组治疗总有效率高于对照组(P<0.05)。结论自我效能管理应用于恶性肿瘤放化疗患者中效果较好,可有效缓解癌痛症状,提升生活质量。

规范化疼痛管理联合临终关怀对晚期胃癌患者疼痛缓解及生活质量的影响

目的:针对晚期胃癌患者出现疼痛、生活质量低下特点,分析规范化疼痛管理+临床关怀护理干预方案的应用价值。方法:本次研究开展于2021年5月~2022年1月时间阶段,就此阶段收治的晚期胃癌80例纳入此次研究。基于硬币正反原则分为2组,各有40例患者,分别接受常规护理(护理A组)和联合护理方案(护理B组)(疼痛管理+临终关怀)。记录不同护理干预方式下患者症状改善变化差异。结果:就2组胃癌患者接受不同护理的影响进行分析发现,在关于疼痛症状缓解方面,护理B组缓解效果明显,且生活质量得分显著较高(P<0.05)。结论:针对患者出现的癌痛症状,实施规范化护理管理,能帮助缓解患者癌痛,配合临终关怀的有效干预,能促使患者直面未来。

博尔宁胶囊治疗32例非小细胞肺癌疗效观察

目的:观察博尔宁胶囊治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效。方法:治疗组32例晚期NSCLC患者服用博尔宁胶囊与对照组28例晚期NSCLC患者支持对症治疗进行对比研究。结果:肿瘤客观疗效:治疗组近期稳定率为59.4%,对照组为35.7%;生活质量:两组治疗前后Karnofsky评分变化比较,治疗组好转率为53.1%,对照组好转率为35.7%;疼痛情况:治疗前治疗组有26例合并癌痛症状,对照组有22例合并癌痛症状,治疗后治疗组癌痛控制有效率为80.8%,对照组为59.1%。结论:博尔宁胶囊能明显提高肿瘤稳定率和好转率,减轻癌痛症状。

Symptoms of Early Cancer Especially Barrett’s Carcinoma

The incidence of the adenocarcinoma of the esophagus (AC) has been rising exponentially in the Western World within the last 30 years. The reasons for this increase are not yet understood. Massive and long lasting gastroesophageal re?ux causes the Barrett’s esophagus which is considered to be a precancerosis. Therefore early diagnosis and appropriate treatment of gastroesophageal re?ux is essential for the prevention of this tumor. This makes heartburn the leading clinical symptom in the patient’s history. In patients with heartburn it is possible to early endoscopically diagnose a Barrett’s esophagus or adenocarcinoma of the esophagus. However only few patients with this increased risk receive an index-endoscopy. In clinical studies a high rate of early carcinomas could be found and could be treated with mucosectomie or ablation. The majority of patients with AC present with symptoms suggestive of progressed disease such as dysphagia or weight loss. The prognosis in patients in late disease stages are with a 5-year survival of only 30% far worse than in patients with early carcinoma (85%). However the early symptoms such as heartburn or regurgitation are unspeci?c and make an e?ective diagnostical strategy di?cult. To optimize screening it would be bene?cial to identify patients with high risk for the development of adenocarcinoma of the esophagus.